A Phase I Study of TAS-102 in Solid Tumors

Phase 1 Completed 15 enrolled Taiho Pharmaceutical Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate the pharmacokinetics of TAS-102 after single and multiple dose in Chinese patients with solid tumor.

Timeline

Start: 2014-09
Primary completion: 2015-10
Completion: 2017-06

Publications

Wang X, Zhou J, Li Y, Ge Y, Zhou Y, Bai C, Shen L. Pharmacokinetics, Safety, and Preliminary Efficacy of Oral Trifluridine/Tipiracil in Chinese Patients with Solid Tumors: A Phase 1b, Open-Label Study. Clin Pharmacol. 2020 Apr 9;12:21-33. doi: 10.2147/CPAA.S232104. eCollection 2020.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TAS-102	Small molecule	35 mg/m2	Oral

Indications

No indication recorded.